Skip to main content
ConductScienceScienceDex

Midori Kato-maeda

NIH Rank #17738
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 8866349Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Internal Medicine

NIH Funding · FY2026

Linked Award Amount
$632.8K
Full award amounts, FY2026
Award Records
3
Records listing this PI
Award-Linked Rank
#17,738
By linked amount among FY2026 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Midori Kato-maeda. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2026 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2026 award records by amount

NIH award records listing Midori Kato-maeda as a PI. Multi-PI records show the full award amount for context.

  • 5R01AI176409-04R01
    Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker
    University of California, San Francisco
    $343.4K
    award amount
  • 3R01AI176409-04S1R01
    Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker
    University of California, San Francisco
    $153.1K
    award amount
  • 3R01AI176409-04S2R01
    Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker
    University of California, San Francisco
    $136.3K
    award amount

Award organization

Organizations that administered FY2026 awards listing Midori Kato-maeda as a PI.

FY2026 award administered by University of California, San Francisco (CA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    University of California, San Francisco
  2. 2024
    $500K Cumulative Funding
  3. 2025
    $1M Cumulative Funding
  4. 2025
    R01 Grant Holder

Explore further

Find collaborators for Midori Kato-maeda

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →